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Historical Significance
Historical NASA drug stability studies suggested that spaceflight conditions 
compromise medication safety and efficacy (Putcha et al, 2001 – 2011). 
Historical NASA ground analog experiments designed to simulate the 
effects of high-energy radioactive particles on medications during 
spaceflight, suggested that radiation exposure during spaceflight could 
threaten drug quality and potency on long-duration exploration missions 
(Putcha et al, 2006).
Follow-on NASA flight studies revealed reduced active pharmaceutical 
ingredient (API) concentrations, and altered drug release; when compared 
to matching ground controls (Putcha et al, 2006 – 2011). 
Purpose
Uncertainty remains regarding space radiation impacts on drug stability and 
shelf life
Space environmental analog and ground-based targeted radiation research 
could reveal valuable insight into drug safety and effectiveness
• In 2017, the Exploration Medical Capability (ExMC) Element designed a three-year 
pilot analog experiment to expose medications to a series of simulated Galactic Cosmic 
Radiation (GCR) mixed-species beam exposures at the NASA Space Radiation 
Laboratory (NSRL) at Brookhaven National Laboratory (BNL) 
o First time-point analysis completed 2018; presented IWS 2019
o Second time-point analysis completed 2019; presented IWS 2020
Research Objectives
Evaluate if the effects of ground-based rapid-switching radiation 
beam exposures can effectively reproduce previously observed 
effects of spaceflight radiation on drug stability and shelf life.
Further evaluate the utility of simulated GCR beam exposures 
as an effective ground-based analog for predicting the impacts 
of GCR exposure on drug stability and shelf life during 
spaceflight.
Materials and Methods
Study Drugs:  
Four medications were prioritized and selected based on:
• Pharmaceutical stability profiles confirmed by previous research / literature
• Clinical relevance for exploration spaceflight
Table A.  Experimental Drug List
• Sets (identical brands / lots) of each drug product procured for each experimental arm
o Sufficient quantities to provide a statistically significant number of replicates
 50-100 dosage units / package
 4 different drugs x 2 packages each x 4 different study conditions = 32 packages of drugs 
• Packaged (as closely as possible) to resemble flight medical systems operational packaging 
(e.g. drug flight bottles / plastic bags / unit-dose strips, etc.).  
Materials and Methods
Study Design:  Four Experimental Arms
1. Non-irradiated JSC Control Group
2. Non-irradiated Traveling Control Group
3. Irradiation Group I (Mixed-beam 0.5Gy Total Dose)
4. Irradiation Group II (Mixed-beam 1.0Gy Total Dose)
Environmental Monitoring
Temperature / RH:  
• Shipment / Storage:  USP <659> "Packaging and Storage Requirements” defined conditions for 
“controlled room temperature” (15 - 30° C, 30 - 65% RH)
o Environmental condition tracking 
o Environmentally controlled storage chambers 
Radiation:
• Detection and Monitoring:  Thermoluminescence Dosimeters (TLD-100 LiF:Mg,Ti)
o TLDs enclosed in clear gelatin capsules, attached to front and / or back, of each drug product package
RH = Relative Humidity USP = United States Pharmacopeia
Materials and Methods
Irradiation:
First experiment at NSRL to utilize the mixed-
species simulator:
Exposure dose: Two mixed-beam radiation doses
• 0.5 Gy
• 1.0 Gy
GCR-like beam profile:
• 1H, 4He, 12C, 16O, 28Si, 48Ti, and 56Fe
Dose detection and monitoring:   
Thermoluminescence Dosimeters (TLD-100 
LiF:Mg,Ti)
• TLDs enclosed in clear gelatin capsules, attached to front 
and / or back, of each drug product package
Figure 2.0:  NSRL GCR Simulation Beam Composition
Figure 3.0:  Irradiation Dose Measurement_TLD Placement
Materials and Methods
Drug Stability Analyses: USP monograph Test methods 
developed for all analyses
API chemical content (Liquid Chromatography:  UPLC H-Class System 
with PDA Detector)
• Trial runs to validate USP method suitability 
• Assay methods validated using commercial chemical reference standards
Presence of impurities or degradation products
• Assessment of chromatographic peak percentages
• Drug formulation component chromatogram overlays
Dissolution testing to determine API release characteristics
• Hanson Vision Elite 8 dissolution apparatus
• Ultraviolet–visible (UV / Vis) Spectrophotometer to assist with dissolution assessments
Preliminary Results Drug Type Exposure TLD-100 
Measured 
Dose 
(mGy) 
TLD-100 
Mean Dose 
(mGy) 
TLD-100 
Ratio 
Back/Front 
Nominal 
NSRL 
Dose 
(mGy) 
Acetaminophen 
500mg 
A3a_Front 465.3 ± 6.3 448.1 ± 6.1 0.93 ± 0.02 500 
A3a_Back 431.0 ± 5.9 500 
A3b_Back 412.7 ± 5.6 412.7 ± 8.8 N/A 500 
Acetaminophen 
500mg 
A4a_Front 932.4 ± 12.7 899.2 ± 9.8 0.93 ± 0.02 1000 
A4a_Back 866.0 ± 11.8 1000 
A4b_Back 843.9 ± 11.5 843.9 ± 11.5 N/A 1000 
Amoxicillin 
500mg 
B3a_Front 436.2 ± 5.9 400.7 ± 5.5 0.84 ± 0.02 500 
B3a_Back 365.2 ± 5.0 500 
B3b_Back 371.9 ± 5.1 371.9 ± 5.1 N/A 500 
Amoxicillin 
500mg 
B4a_Front 864.4 ± 11.7 804.4 ± 9.0 0.86 ± 0.02 1000 
B4a_Back 744.4 ± 10.1 1000 
B4b_Back 747.0 ± 10.2 747.0 ± 10.2 N/A 1000 
Ibuprofen 
400mg 
C3a_Front 422.7 ± 5.7 405.7 ± 5.5 0.92 ± 0.02 500 
C3a_Back 388.8 ± 5.3 500 
C3b_Back 394.4 ± 5.4 394.4 ± 5.4 N/A 500 
Ibuprofen 
400mg 
C4a_Front 871.5 ± 11.8 822.6 ± 9.2 0.89 ± 0.02 1000 
C4a_Back 773.7 ± 10.5 1000 
C4b_Back 733.3 ± 10.0 733.3 ± 10.0 N/A 1000 
Levofloxacin 
500mg 
D3a_Front 432.0 ± 5.9 412.6 ± 5.6 0.91 ± 0.02 500 
D3a_Back 393.2 ± 5.3 500 
D3b_Back 384.0 ± 5.2 384.0 ± 5.2 N/A 500 
Levofloxacin 
500mg 
D4a_Front 856.8 ± 11.6 855.5 ± 9.0 1.00 ± 0.02 1000 
D4a_Back 854.2 ± 11.6 1000 
D4b_Back 711.0 ± 9.7 711.0 ± 9.7 N/A 1000 
Promethazine 
25mg 
E3a_Front 448.4 ± 6.1 413.8 ± 5.6 0.85 ± 0.02 500 
E3a_Back 379.2 ± 5.2 500 
E3b_Back 400.4 ± 5.4 400.4 ± 5.4 N/A 500 
Promethazine 
25mg 
E4a_Front 923.6 ± 12.6 847.5 ± 9.7 0.84 ± 0.02 1000 
E4a_Back 771.5 ± 10.5 1000 
E4b_Back 769.4 ± 10.5 769.4 ± 10.5 N/A 1000 
 Note: The TLD measured dose values include the control dose subtraction, no additional 
corrections needed.
Table C:  Summary of TLD-100 Dose Measurement Results
Irradiation Dose Measurements
• Entrance dose for irradiated drugs at 
the 500 mGy dose:   422.7 ± 5.7 -
465.3 ± 6.3 mGy
o a measured dose of 7-15% lower than 
the expected nominal dose (500 mGy) 
• Entrance dose for irradiated drugs at 
the 1000 mGy dose:   856.8 ± 11.6 -
932.4 ± 12.7 mGy
o a measured dose of 7-14% lower than 
the expected nominal dose (1000 mGy)  
• A dose-decreasing trend between the 
front and back TLDs of 7 – 16% was 
observed for each drug group.
Preliminary Results
API Content Analysis:  API content for all irradiated and control study medications tested at time-points 
(t1- t2) met the USP acceptance criteria for potency, or percentage of label claimed API content:
The specification limit for change in potency usually ≤ 10%. (Waterman KC, Swanson JT, Lippold BL. A scientific and statistical analysis of accelerated aging for pharmaceuticals. Part 1: accuracy of fitting methods. J Pharm Sci 2014 
Oct;103(10):3000-6).
SAMPLE PRODUCT 
NAME
STUDY ARM % LABEL 
CLAIM API 2018
% LABEL 
CLAIM API 2019
% CHANGE IN 
POTENCY (t2-t1 / t1)
% API USP 
REQUIREMENT
RESULT 
OUTCOME
A1A Acetaminophen      
500 mg Tablet
Non-Irradiated         
JSC Control
95.3 103.22 ↑8.31 90-110 Pass
A1B Acetaminophen      
500 mg Tablet
Non-Irradiated         
JSC Control
100.4 101.85 ↑1.44 90-110 Pass
A2A Acetaminophen      
500 mg Tablet
Non-Irradiated      
Travel Control
97.08 102.18 ↑5.25 90-110 Pass
A2B Acetaminophen      
500 mg Tablet
Non-Irradiated      
Travel Control
97.73 102.81 ↑5.2 90-110 Pass
A3A Acetaminophen      
500 mg Tablet
Irradiation Group I 
(Mixed-beam 0.5 GY
100.18 102.45 ↑2.27 90-110 Pass
A3B Acetaminophen      
500 mg Tablet
Irradiation Group I 
(Mixed-beam 0.5 GY
96.51 99.86 ↑3.47 90-110 Pass
A4A Acetaminophen      
500 mg Tablet
Irradiation Group II 
(Mixed-beam 1.0 GY
95.76 102.4 ↑6.93 90-110 Pass
A4B Acetaminophen      
500 mg Tablet
Irradiation Group II 
(Mixed-beam 1.0 GY
103.67 99.32 ↓4.2 90-110 Pass
SAMPLE PRODUCT 
NAME
STUDY ARM % LABEL 
CLAIM API 2018
% LABEL 
CLAIM API 2019
% CHANGE IN 
POTENCY (t2-t1) / t1
% API USP 
REQUIREMENT
RESULT 
OUTCOME
B1a Amoxicillin       
500 mg Capsules
Non-Irradiated      
JSC Control
100.16 102.08 ↑1.92 90-120 Pass
B1b Amoxicillin       
500 mg Capsules
Non-Irradiated      
JSC Control
97.44 98.58 ↑1.17 90-120 Pass
B2a Amoxicillin       
500 mg Capsules
Non-Irradiated     
Travel Control
100.96 101.51 ↑0.54 90-120 Pass
B2b Amoxicillin       
500 mg Capsules
Non-Irradiated     
Travel Control
100.04 100.02 ↑0.02 90-120 Pass
B3a Amoxicillin       
500 mg Capsules
Irradiation Group I 
(Mixed-beam 0.5 GY
101.57 99.68 ↓1.86 90-120 Pass
B3b Amoxicillin       
500 mg Capsules
Irradiation Group I 
(Mixed-beam 0.5 GY
99.31 97.11 ↓2.25 90-120 Pass
B4a Amoxicillin       
500 mg Capsules
Irradiation Group II 
(Mixed-beam 1.0 GY
98.74 98.97 ↑0.23 90-120 Pass
B4b Amoxicillin       
500 mg Capsules
Irradiation Group II 
(Mixed-beam 1.0 GY
102.42 93.72 ↓8.49 90-120 Pass
SAMPLE PRODUCT 
NAME
STUDY ARM % LABEL 
CLAIM API 2018
% LABEL 
CLAIM API 2019
% CHANGE IN 
POTENCY (t1-t2 / t1)
% API USP 
REQUIREMENT
RESULT 
OUTCOME
C1a Ibuprofen       
400 mg Tablets
Non-Irradiated      
JSC Control
103.85 98.24 ↓5.40 90-110 Pass
C1b Ibuprofen       
400 mg Tablets
Non-Irradiated      
JSC Control
106.6 102.94 ↓3.43 90-110 Pass
C2a Ibuprofen       
400 mg Tablets
Non-Irradiated   
Travel Control
109.32 97.21 ↓11.08 90-110 Pass
C2b Ibuprofen       
400 mg Tablets
Non-Irradiated   
Travel Control
103.84 101.37 ↓2.38 90-110 Pass
C3a Ibuprofen       
400 mg Tablets
Irradiation Group I 
(Mixed-beam 0.5 GY
106.6 96.98 ↓9.02 90-110 Pass
C3b Ibuprofen       
400 mg Tablets
Irradiation Group I 
(Mixed-beam 0.5 GY
109.31 96.96 ↓11.3 90-110 Pass
C4a Ibuprofen       
400 mg Tablets
Irradiation Group II 
(Mixed-beam 1.0 GY
104.38 95.15 ↓8.84 90-110 Pass
C4b Ibuprofen       
400 mg Tablets
Irradiation Group II 
(Mixed-beam 1.0 GY
106.43 95.37 ↓10.39 90-110 Pass
SAMPLE PRODUCT 
NAME
STUDY ARM % LABEL 
CLAIM API 2018
% LABEL 
CLAIM API 2019
% CHANGE IN 
POTENCY (t2-t1 / t1)
% API USP 
REQUIREMENT
RESULT 
OUTCOME
E1a Promethazine 
25 mg Tablets
Non-Irradiated      
JSC Control
99.17 100.2 ↑1.04 95-110 Pass
E1b Promethazine 
25 mg Tablets
Non-Irradiated      
JSC Control
104.66 101.39 ↓3.12 95-110 Pass
E2a Promethazine 
25 mg Tablets
Non-Irradiated Travel 
Control
107.32 100.09 ↓6.73 95-110 Pass
E2b Promethazine 
25 mg Tablets
Non-Irradiated Travel 
Control
104.33 100.68 ↓3.49 95-110 Pass
E3a Promethazine 
25 mg Tablets
Irradiation Group I 
(Mixed-beam 0.5 GY
103 104.02 ↑0.99 95-110 Pass
E3b Promethazine 
25 mg Tablets
Irradiation Group I 
(Mixed-beam 0.5 GY
109.53 101 ↓7.79 95-110 Pass
E4a Promethazine 
25 mg Tablets
Irradiation Group II 
(Mixed-beam 1.0 GY
108.33 102.3 ↓5.57 95-110 Pass
E4b Promethazine 
25 mg Tablets
Irradiation Group II 
(Mixed-beam 1.0 GY
107.3 100.53 ↓6.31 95-110 Pass
Preliminary Results
Drug Stability Analyses:  Assessment of drug component chromatograms at t1 – t2
revealed no new or foreign peaks in any of the irradiated drug product samples
Acetaminophen
2018 2019
Preliminary Results
Drug Stability Analyses Continued:  Amoxicillin
2018 2019
Preliminary Results
Drug Stability Analyses Continued:  Ibuprofen
2018 2019
Preliminary Results
Drug Stability Analyses Continued:  Promethazine
2018 2019
Preliminary Results
Dissolution:  All samples met the USP requirement for Dissolution.  
Some amoxicillin samples revealed “significant changes” in release between t1 and t2
Acetaminophen: Amoxicillin:
Sample Product Name Sample Name % Dissolved   
2018
2018 Standard 
Deviation (n=6)
% Dissolved   
2019
2019 Standard 
Deviation (n=6)
% Change in 
Dissolution
USP Standard    
(≥ 80%)
A1a Acetaminophen      500 mg Tablets
Non-irradiated JSC 
Control Group
99.51 1.10% 102.54 1.07% 3.04 Pass
A1b Acetaminophen      
500 mg Tablets
Non-irradiated JSC 
Control Group
100.71 3.56% 100.4 1.24% 0.31 Pass
A2a
Acetaminophen      
500 mg Tablets
Non-irradiated  
Traveling Control Group
100.12 2.95% 101.09 1.49% 0.97 Pass
A2b Acetaminophen      500 mg Tablets
Non-irradiated Traveling      
Control Group
100.77 4.48% 99.47 2.08% 1.29 Pass
100.43 0.92
101.19
2.2
0.34
5.54
Pass
2.19%
99.51 2.81%A4a Acetaminophen      500 mg Tablets
A4b Acetaminophen      500 mg Tablets
Pass
1.56%
2.08%
Irradiation Group II                 
(Mixed-beam 1.0Gy 
 Irradiation Group II                 
(Mixed-beam 1.0Gy 
 
95.45 4.47% 100.74
A3a Acetaminophen      500 mg Tablets
Pass
A3b Acetaminophen      500 mg Tablets
Pass
1.67%
0.86%
Irradiation Group I                 
(Mixed-beam 0.5Gy 
 Irradiation Group I                
(Mixed-beam 0.5Gy 
 
102.75 4.01% 100.49
100.85
Sample Product Name Sample Name % Dissolved   
2018
2018 Standard 
Deviation (n=6)
% Dissolved   
2019
2019 Standard 
Deviation (n=6)
% Change in 
Dissolution
USP Standard    
(≥ 80%)
B1a Amoxicillin                500 mg Capsules
Non-irradiated JSC 
Control Group
100.16 5.78% 93.43 2.12% ↓6.72 Pass
B1b Amoxicillin                500 mg Capsules
Non-irradiated JSC 
Control Group
97.44 5.06% 92.18 4.53% ↓5.4 Pass
B2a Amoxicillin                500 mg Capsules
Non-irradiated                      
Traveling Control Group
100.96 4.63% 89.69 3.16% ↓11.16 Pass
B2b Amoxicillin                500 mg Capsules
Non-irradiated                      
Traveling Control Group
100.04 4.70% 92.80 1.65% ↓7.24 Pass
86.13
88.59
99.31 5.46%
101.57 6.17% 91.25
91.05
4.53%
2.49%
Pass
Pass
Pass
Pass
3.89%
5.43%
2.77%
5.18%
↓10.16
↓8.32
↓12.78
↓13.5
B3a Amoxicillin                500 mg Capsules
B3b Amoxicillin                500 mg Capsules
Irradiation Group I                   
(Mixed-beam 0.5Gy Total 
Irradiation Group I                   
(Mixed-beam 0.5Gy Total 
B4a Amoxicillin                500 mg Capsules 98.74
B4b Amoxicillin                500 mg Capsules 102.42
Irradiation Group II                   
(Mixed-beam 1.0 Gy Total 
Irradiation Group II                   
(Mixed-beam 1.0 Gy Total 
Preliminary Results
Drug Stability Analyses Continued:
Ibuprofen: Promethazine:
Sample Product Name Sample Name 2018% 
Dissolved
2018 Standard 
Deviation (n=6)
2019% 
Dissolved
2019Standard 
Deviation (n=6)
% Change in 
Dissolution
USP Standard    
(≥ 80%)
C1a
Ibuprofen         
400 mg Tablets
Non-irradiated           
JSC Control Group
100.64 1.32% 98.23 0.20% ↓2.39 Pass
C1b
Ibuprofen         
400 mg Tablets
Non-irradiated           
JSC Control Group
100.97 0.95% 98.17 0.16% ↓2.77 Pass
C2a
Ibuprofen         
400 mg Tablets
Non-irradiated                      
Traveling Control Group
100.38 1.52% 98.11 0.00% ↓2.26 Pass
C2b
Ibuprofen         
400 mg Tablets
Non-irradiated                      
Traveling Control Group
100.58 2.39% 98.55 0.38% ↓2.02 Pass
Pass
C3a
Ibuprofen         
400 mg Tablets
Irradiation Group I                   
(Mixed-beam 0.5Gy 
 
98.74 Pass
C3b
Ibuprofen         
400 mg Tablets
Irradiation Group I                   
(Mixed-beam 0.5Gy 
 
98.86
100.49
100.59
0.40%
0.42%
Pass
C4a
Ibuprofen         
400 mg Tablets
Irradiation Group II                   
(Mixed-beam 1.0 Gy 
 
98.99 Pass
C4b
Ibuprofen         
400 mg Tablets
Irradiation Group II                   
(Mixed-beam 1.0 Gy 
 
99.05
100.53
100
0.71%
0.86%
↓1.74
↓1.72
↓1.53
↓0.95
1.92%
3.26%
1.36%
2.66%
Sample Product Name Sample Name 2018 % 
Dissolved
2018 Standard 
Deviation (N=6)
2019 % 
Dissolved
2019 Standard 
Deviation (N=6)
% Change in 
Dissolution
USP Standard    
(≥ 80%)
E1a Promethazine 
25 mg Tablets
Non-irradiated                
JSC Control Group
98.48 0.92% 103.46 0.53% ↑5.05 Pass
E1b Promethazine 
25 mg Tablets
Non-irradiated                
JSC Control Group
98.38 0.58% 103.95 0.68% ↑5.66 Pass
E2a Promethazine 
25 mg Tablets
Non-irradiated                      
Traveling Control Group
98.21 2.13% 102.94 0.46% ↑4.82 Pass
E2b Promethazine 
25 mg Tablets
Non-irradiated                      
Traveling Control Group
98.69 1.35% 103.93 0.36% ↑5.31 Pass
E3b Promethazine 
25 mg Tablets
Irradiation Group I                   
(Mixed-beam 0.5Gy Total 
104.03 0.59%98.58 0.80%
E3a Promethazine 
25 mg Tablets
Irradiation Group I                   
(Mixed-beam 0.5Gy Total 
103.90 0.32%98.12 1.69%
E4b Promethazine 
25 mg Tablets
Irradiation Group II                   
(Mixed-beam 1.0 Gy Total 
103.46 0.53%98.48 0.62%
E4a Promethazine 
25 mg Tablets
Irradiation Group II                   
(Mixed-beam 1.0 Gy Total 
103.50 0.51%98.41 1.47%
↑5.89
↑5.53
↑5.17
↑5.05 Pass
Pass
Pass
Pass
Preliminary Results
Drug Degradation Products / Impurities:
 Impurities peak percent calculations, and overlay chromatograms revealed no foreign or new peaks in 
any of the irradiated samples during the first two time-point analyses.
Acetaminophen: 2018 2019
ND = “Not Detected”
Preliminary Results
Drug Degradation Products / Impurities :
Amoxicillin: 2018 2019
Preliminary Results
Drug Stability Analyses Continued:  Drug Degradation Products / Impurities
Ibuprofen: 2018 2019
Preliminary Results
Drug Stability Analyses Continued:  Drug Degradation Products / Impurities
Promethazine: 2018 2019
Preliminary Conclusions
Results revealed that the simulated GCR exposure did not facilitate non-
characteristic degradation two years post radiation exposure.
• Two study drugs (Amoxicillin, Ibuprofen) approached labeled expiration dates, none had 
expired prior to t2 stability testing (09/16/19).
• “Lag-time” degradation is characteristic of some solid dosage forms.
Uncertainties regarding the extent and rate of drug degradation for the tested 
medications may be further clarified by t3 testing.
The observed results from t1 and t2 drug stability analyses, concur with those 
from previous JSC stability studies: 
• Differences in API potency between spaceflight and ground-controlled drug samples(Du et al, 
2011)
• Differences in API potency between irradiated and non-irradiated control drug samples 
simulated single-beam radiation ground-analog studies (Putcha et al, 2006).
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Introduction
Pharmaceutical “Drug” Stability:  The chemical and physical integrity of 
a drug dosage unit, or finished pharmaceutical product (FPP).  
 Drug stability testing evaluates how drug quality varies as a function of time and storage 
conditions (e.g., temperature, humidity, radiation) 
 FDA Monographs for all approved drugs are in the United States Pharmacopeia (USP); which 
includes acceptance criteria for the API (ICH Q1A R2, “Stability Testing of New Drug 
Substances”)
o Failure to meet the acceptance criteria for potency, presence of degradation products, 
and dissolution is considered a “significant change” for an FPP
 Chromatographic methods provide quantitative and qualitative analysis of drug substances
o The most common chromatographic method for stability studies uses HPLC with UV 
detection
 A dissolution or API release test measures the extent and rate of solution formation from a solid 
(e.g. tablet, capsule) or semi-solid (e.g. cream, ointment) FPP
o Changes in API release from a FPP can influence bioavailability and therapeutic 
effectiveness
Introduction
Photostability refers to how a drug compound responds to 
radiation exposure…..(Glass et al., 2004)
 Exposure to high-intensity electromagnetic radiation may cause 
significant loss of the API, and initiate formation of degradation
products (M Jamrógiewicz, 2016)
 Drug photodecomposition can lead to:
o Loss of API potency which could lead to a reduction in therapeutic activity
o Degradation product contamination leading to adverse drug experiences 
(van Henegouwen, 1997; Moan, 1996; Kullavanijaya and Lim, 2005)
Materials and Methods
Study Design:  Four Experimental Arms
1. Non-irradiated JSC Control Group
2. Non-irradiated Traveling Control Group
3. Irradiation Group I (Mixed-beam 0.5Gy Total Dose)
4. Irradiation Group II (Mixed-beam 1.0Gy Total Dose)
Environmental Monitoring
Temperature / RH:  
• Shipment / Storage:  USP <659> "Packaging and Storage Requirements” defined conditions for 
“controlled room temperature” (15 - 30° C, 30 - 65% RH)
o Courier tracking:  Sensitech Temp Tale®4 temperature tracker
o Project tracking:  HOBO U12-012 environmental tracking device
o JSC storage:  Environmental chambers (Darwin, Model KB0303-AA-DA, Sanyo, model MLR-350H
o Analytical vendor storage:  Caron Environmental Chamber, Model 7000-10
Radiation:
• Detection and Monitoring:  Thermoluminescence Dosimeters (TLD-100 LiF:Mg,Ti)
o TLDs enclosed in clear gelatin capsules (Lilly, No. 0, NDC 00002240702); and attached to front and / or back, of 
each drug product package
Materials and Methods
Dissolution testing to determine API release characteristics
• Hanson Vision Elite 8 dissolution apparatus
• Ultraviolet–visible (UV / Vis) Spectrophotometer to assist with dissolution 
assessments
o UV/Vis refers to absorption spectroscopy or reflectance spectroscopy in part of the 
ultraviolet and the full, adjacent visible spectral regions. Direct UV/VIS
spectrophotometric determination of absorbance has been the traditional analytical 
method for dissolution testing
Preliminary Results
Environmental Control:
Transport / Storage temperatures / RH on average remained within USP 
limits for “controlled room temperature” throughout the experimental timeline.
 Temperatures:  18.9°C – 28.8°C
 RH:  4% - 79% (transport from JSC to analytical vendor only)
o Only brief excursions (< 24 hours) above RH upper and lower limits
Irradiation Dose Measurements
 Entrance dose for irradiated drugs at the 0.5 Gy dose:   422.7 ± 5.7 - 465.3 ± 6.3 mGy
o a measured dose of 7-15% lower than the expected nominal dose (500 mGy) 
 Entrance dose for irradiated drugs at the 1.0 Gy dose:   856.8 ± 11.6 - 932.4 ± 12.7 mGy,
o a measured dose of 7-14% lower than the expected nominal dose (1000 mGy)  
 A dose-decreasing trend between the front and back TLDs of 7 – 16% was observed for 
each drug group.
